Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04560062
Other study ID # ERC-2018-STG-804761.2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 13, 2020
Est. completion date June 30, 2022

Study information

Verified date January 2021
Source Universidad Miguel Hernandez de Elche
Contact Lucy Anne Parker
Phone +34 965919516
Email lparker@umh.es
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This protocol reflects the second part of a larger mixed-methods study aimed at exploring the process by which global recommendations can be translated into context-specific, evidence-informed action for diabetes prevention in low-resource settings. Firstly, a retrospective cohort study will assess the current level of implementation of comprehensive diabetes care over a 24-month period (2019-2020), by describing healthcare received and health outcomes of a representative sample of diabetes patients currently accessing care in the study region. Focus groups prompted by the findings of the retrospective study will be used to inspire local innovations which will be evaluated through a prospective follow-up of the cohort.


Description:

Objective: To evaluate the implementation of comprehensive diabetes care in two low-resource settings in Ecuador. Specific objectives: 1. To assess patient outcomes including biochemical diabetes control and health-related quality of life. 2. To evaluate diabetes-related health care access. 3. To assess complications related to diabetes. Sample size: The sample size is proposed conservatively to ensure a precision to estimate outcomes of 50% with an absolute precision of ±5%, assuming a design effect of 1.2 and potential loss of 20%. Sample design: A representative sample for each district will be obtained by stratified single-stage cluster sampling. The clusters are health facilities for which a sample of patients will randomly selected. The sample will be stratified by facility type (Ministry of Public Health (MSP) facilities, or Social Security facilities for affiliated workers) in Quito and by Rural/Urban setting in Esmeraldas. Patient sampling will use the electronic consultation registry of each selected facility where possible. Data unavailable in the electronic registers will be extracted from any available paper files. Data collection procedure: Research assistants will obtain the data mainly from health services records, which will be supplemented by patient interviews including socio-demographic and clinical data, perceived social support (the Multidimensional Scale of Perceived Social Support, MSPSS) and health-related quality of life (the Diabetes Health Profile-18, DHP-18) profile. They will collect data regarding whether the patient received regular review by a clinician, and underwent screening for diabetes complications as recommended in the 2017 Clinical Practice Guideline for Type 2 Diabetes in Ecuador. He/she will record the date and details of any complications and experiences over the course of the evaluation and other clinical data such as comorbidities, treatments or patient management by a multidisciplinary health care team. The first data collection will be retrospective and will include diabetes-related health care and clinical outcomes during 2019 and 2020. Clinical files will be reviewed every 12 months for the duration of follow-up (2 years). Supplementary interview data will be assessed on a baseline and in the last 6 months of follow-up. Analysis: The researchers will calculate the proportion of patients that received care as per the clinical practice guideline (CPG) recommendations and/or the proportion receiving an intermediate level of care (as required). Proportions will be described with 95% confidence intervals. Variation in healthcare received and diabetes-related health will be described using sociodemographic and clinical characteristics of the patients to highlight potential inequities. A multivariate logistic regression model may be used to explore the relationship between the primary outcomes and socioeconomic explanatory variable and/or type of health facility. If necessary, the researchers will adjust for potential confounders such as patients' factors (e.g. sex, age, comorbidity, perceived social support) and/or environmental factors (e.g. proximity to the health centre, availability of different medical specialties or methods as laboratory test). Statistical analysis will be performed using Stata/SE (StataCorp, College Station, TX, USA) Version 15.


Recruitment information / eligibility

Status Recruiting
Enrollment 1152
Est. completion date June 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Individuals diagnosed with type-2 diabetes. - Age over 18 years. - Patients are accessing diabetes care in health facilities in the study districts. - Providing informed consent Exclusion Criteria: - Unability to provide informed consent (e.g. significant mental impairment). - Pregnant women if they are diagnosed with gestational diabetes.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Spontaneous changes in diabetes-related health care
The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.

Locations

Country Name City State
Ecuador Mari Carmen Bernal Soriano Esmeraldas

Sponsors (4)

Lead Sponsor Collaborator
Universidad Miguel Hernandez de Elche Centro de Epidemiología Comunitaria y Medicina Tropical, European Research Council, Pontificia Universidad Católica del Ecuador

Country where clinical trial is conducted

Ecuador, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with biochemically controlled disease Proportions of patients with controlled disease along with 95% confidence interval.
Controlled disease is defined according to the last laboratory result as glycated haemoglobin <7% or <8% if =15 years of evolution or complications and serious comorbidities; or fasting blood glucose: 70 - 130 mg/dl or postprandial blood glucose <180 mg/dl.
Year 1
Primary Proportion of patients with biochemically controlled disease Proportions of patients with controlled disease along with 95% confidence interval.
Controlled disease is defined according to the last laboratory result as glycated haemoglobin <7% or <8% if =15 years of evolution or complications and serious comorbidities; or fasting blood glucose: 70 - 130 mg/dl or postprandial blood glucose <180 mg/dl.
Year 2
Primary Proportion of patients with biochemically controlled disease Proportions of patients with controlled disease along with 95% confidence interval.
Controlled disease is defined according to the last laboratory result as glycated haemoglobin <7% or <8% if =15 years of evolution or complications and serious comorbidities; or fasting blood glucose: 70 - 130 mg/dl or postprandial blood glucose <180 mg/dl.
Year 3
Primary Proportion of patients with biochemically controlled disease Proportions of patients with controlled disease along with 95% confidence interval.
Controlled disease is defined according to the last laboratory result as glycated haemoglobin <7% or <8% if =15 years of evolution or complications and serious comorbidities; or fasting blood glucose: 70 - 130 mg/dl or postprandial blood glucose <180 mg/dl.
Year 4
Primary Proportion of patients with optimal health-related quality of life Health-related quality of life will be obtained with Diabetes Health Profile-18 (DHP-18) questionnaire. DHP-18 scores range from 0 to 100, with 0 representing no dysfunction and 100 maximum dysfunction.
Proportion of patients with total final score under the median, meaning lower dysfunction, along with 95% confidence interval.
Year 3
Primary Proportion of patients with optimal health-related quality of life Health-related quality of life will be obtained with Diabetes Health Profile-18 (DHP-18) questionnaire. DHP-18 scores range from 0 to 100, with 0 representing no dysfunction and 100 maximum dysfunction.
Proportion of patients with total final score under the median, meaning lower dysfunction, along with 95% confidence interval.
Year 4
Primary Proportion of patients with access to health care of diabetes It includes processes of care indicators that represent the proportion of the patients who undergo the care processes recommended by the CPG to manage the disease. The investigators will obtain the care frequency for each patient during the year of study as a quantitative value and will also categorize those care indicators that are recommended with greater periodicity in the CPG. Year 1
Primary Proportion of patients with access to health care of diabetes It includes processes of care indicators that represent the proportion of the patients who undergo the care processes recommended by the CPG to manage the disease. The investigators will obtain the care frequency for each patient during the year of study as a quantitative value and will also categorize those care indicators that are recommended with greater periodicity in the CPG. Year 2
Primary Proportion of patients with access to health care of diabetes It includes processes of care indicators that represent the proportion of the patients who undergo the care processes recommended by the CPG to manage the disease. The investigators will obtain the care frequency for each patient during the year of study as a quantitative value and will also categorize those care indicators that are recommended with greater periodicity in the CPG. Year 3
Primary Proportion of patients with access to health care of diabetes It includes processes of care indicators that represent the proportion of the patients who undergo the care processes recommended by the CPG to manage the disease. The investigators will obtain the care frequency for each patient during the year of study as a quantitative value and will also categorize those care indicators that are recommended with greater periodicity in the CPG. Year 4
Secondary Perceived social support Results of the standardized questionnaire "the Multidimensional Scale of Perceived Social Support (MSPSS)". The response format is a four-point Likert type scale (1= rarely, 2= sometimes, 3=frequently, 4= always or almost always). A higher score implies a greater perception of social support.
Tertiles of total final score will be used to measure low, medium and high social support. The investigators will report the patient ratio and 95% confidence interval for each category of social support
Year 3
Secondary Perceived social support Results of the standardized questionnaire "the Multidimensional Scale of Perceived Social Support (MSPSS)". The response format is a four-point Likert type scale (1= rarely, 2= sometimes, 3=frequently, 4= always or almost always). A higher score implies a greater perception of social support.
Tertiles of total final score will be used to measure low, medium and high social support. The investigators will report the patient ratio and 95% confidence interval for each category of social support.
Year 4
Secondary Proportion of patients who diabetes-related education received Self-reported information [dichotomous (yes/no) responses]. Proportion of patients who indicate that they have received information on diabetes and healthy habits, along with 95% confidence interval. Year 3
Secondary Proportion of patients who diabetes-related education received Self-reported information [dichotomous (yes/no) responses]. Proportion of patients who indicate that they have received information on diabetes and healthy habits, along with 95% confidence interval. Year 4
Secondary Proportion of patients with blood pressure controlled (<140/90 mmHg) Proportions along with 95% confidence interval. Year 1
Secondary Proportion of patients with blood pressure controlled (<140/90 mmHg) Proportions along with 95% confidence interval. Year 2
Secondary Proportion of patients with blood pressure controlled (<140/90 mmHg) Proportions along with 95% confidence interval. Year 3
Secondary Proportion of patients with blood pressure controlled (<140/90 mmHg) Proportions along with 95% confidence interval. Year 4
Secondary Proportion of patients with BMI between 18.5 and 25 kg/m2 or 5% weight loss if BMI>25 kg/m2 Proportions along with 95% confidence interval. Year 1
Secondary Proportion of patients with BMI between 18.5 and 25 kg/m2 or 5% weight loss if BMI>25 kg/m2 Proportions along with 95% confidence interval. Year 2
Secondary Proportion of patients with BMI between 18.5 and 25 kg/m2 or 5% weight loss if BMI>25 kg/m2 Proportions along with 95% confidence interval. Year 3
Secondary Proportion of patients with BMI between 18.5 and 25 kg/m2 or 5% weight loss if BMI>25 kg/m2 Proportions along with 95% confidence interval. Year 4
Secondary Proportion of patients with LDL cholesterol level < 100 mg/dl Proportions along with 95% confidence interval. Year 1
Secondary Proportion of patients with LDL cholesterol level < 100 mg/dl Proportions along with 95% confidence interval. Year 2
Secondary Proportion of patients with LDL cholesterol level < 100 mg/dl Proportions along with 95% confidence interval. Year 3
Secondary Proportion of patients with LDL cholesterol level < 100 mg/dl Proportions along with 95% confidence interval. Year 4
Secondary Proportion of patients with microalbuminuria level <30 mg/day Proportions along with 95% confidence interval. Year 1
Secondary Proportion of patients with microalbuminuria level <30 mg/day Proportions along with 95% confidence interval. Year 2
Secondary Proportion of patients with microalbuminuria level <30 mg/day Proportions along with 95% confidence interval. Year 3
Secondary Proportion of patients with microalbuminuria level <30 mg/day Proportions along with 95% confidence interval. Year 4
Secondary Number of unscheduled diabetes-related consultations Number of unscheduled due to decompensation of the disease and/or complications. Results will be reported as absolute values. Year 1
Secondary Number of unscheduled diabetes-related consultations Number of unscheduled due to decompensation of the disease and/or complications. Results will be reported as absolute values. Year 2
Secondary Number of unscheduled diabetes-related consultations Number of unscheduled due to decompensation of the disease and/or complications. Results will be reported as absolute values. Year 3
Secondary Number of unscheduled diabetes-related consultations Number of unscheduled due to decompensation of the disease and/or complications. Results will be reported as absolute values. Year 4
Secondary Number of hospitalisations due to diabetes complications Number of hospitalisations owing to decompensation of the disease and/or complications. Results will be reported as absolute values. Year 1
Secondary Number of hospitalisations due to diabetes complications Number of hospitalisations owing to decompensation of the disease and/or complications. Results will be reported as absolute values. Year 2
Secondary Number of hospitalisations due to diabetes complications Number of hospitalisations owing to decompensation of the disease and/or complications. Results will be reported as absolute values. Year 3
Secondary Number of hospitalisations due to diabetes complications Number of hospitalisations owing to decompensation of the disease and/or complications. Results will be reported as absolute values. Year 4
Secondary Proportion of patients with at least one disease complication Disease complications considered will include retinopathy and/or blindness, lower limb amputations, cardiovascular events (such as stroke, myocardial infarction, ischemic heart disease, obstructive artery disease, congestive heart failure) and/or renal dysfunction according to the last glomerular filtration rate result using the MDRD-4 (Modification of Diet in Renal Disease) formula or serum creatinine value.
Proportion along with 95% confidence interval.
Year 1
Secondary Proportion of patients with at least one disease complication Disease complications considered will include retinopathy and/or blindness, lower limb amputations, cardiovascular events (such as stroke, myocardial infarction, ischemic heart disease, obstructive artery disease, congestive heart failure) and/or renal dysfunction according to the last glomerular filtration rate result using the MDRD-4 (Modification of Diet in Renal Disease) formula or serum creatinine value.
Proportion along with 95% confidence interval.
Year 2
Secondary Proportion of patients with at least one disease complication Disease complications considered will include retinopathy and/or blindness, lower limb amputations, cardiovascular events (such as stroke, myocardial infarction, ischemic heart disease, obstructive artery disease, congestive heart failure) and/or renal dysfunction according to the last glomerular filtration rate result using the MDRD-4 (Modification of Diet in Renal Disease) formula or serum creatinine value.
Proportion along with 95% confidence interval.
Year 3
Secondary Proportion of patients with at least one disease complication Disease complications considered will include retinopathy and/or blindness, lower limb amputations, cardiovascular events (such as stroke, myocardial infarction, ischemic heart disease, obstructive artery disease, congestive heart failure) and/or renal dysfunction according to the last glomerular filtration rate result using the MDRD-4 (Modification of Diet in Renal Disease) formula or serum creatinine value.
Proportion along with 95% confidence interval.
Year 4
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2